[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336933-105":59,"doc-detail-336933-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","population-pharmacokinetic-analysis-of-tucatinib-in-healthy-participants-and-patients-with-breast-cancer-or-colorectal-cancer","Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer","","A population pharmacokinetic model was built to characterize tucatinib exposure and explain pharmacokinetic variability in healthy volunteers and in patients with HER2+ metastatic breast or colorectal cancers. Using nonlinear mixed-effects modeling on datasets from four healthy studies and three patient studies, clinically relevant covariates were tested and model fit was assessed via prediction-corrected visual predictive checks. A two-compartment model with linear elimination and first-order absorption with lag time described concentrations in 151 healthy participants and 132 patients, with tumor type affecting bioavailability and clearance.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/population-pharmacokinetic-analysis-of-tucatinib-in-healthy-participants-and-patients-with-breast-cancer-or-colorectal-cancer/336933/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/population-pharmacokinetic-analysis-of-tucatinib-in-healthy-participants-and-patients-with-breast-cancer-or-colorectal-cancer/336933.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of this population pharmacokinetic analysis of tucatinib?","Question",{"text":112,"@type":113},"To characterize tucatinib pharmacokinetics and identify sources of pharmacokinetic variability in healthy participants and patients with HER2+ metastatic breast or colorectal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the population pharmacokinetic model constructed and evaluated?",{"text":117,"@type":113},"A population pharmacokinetic model was developed using nonlinear mixed-effects modeling from four healthy participant studies and three patient studies, then assessed with prediction-corrected visual predictive checks.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors significantly influenced tucatinib exposure in the final model?",{"text":121,"@type":113},"Tumor type was identified as a significant covariate affecting bioavailability and clearance, increasing steady-state exposure in HER2+ metastatic colorectal and breast cancer compared with healthy participants.",{"name":123,"@type":110,"acceptedAnswer":124},"Do clinicians need to adjust the tucatinib dose based on the covariates tested?",{"text":125,"@type":113},"No. The statistically significant covariate effects were not considered clinically meaningful, and no dose adjustments were required based on the covariates evaluated in the final model.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336933,1790762812,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Clinical Pharmacokinetics (2024) 63:1477–1487 [https://doi.org/10.1007/s40262-024-01412-0](https://doi.org/10.1007/s40262-024-01412-0)  \nPopulation Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer  \nDaping Zhang1 · Adekemi Taylor2 · Jie Janet Zhao2 · Christopher J. Endres1,3 · Ariel Topletz‑Erickson1  \nAccepted: 8 August 2024 / Published online: 5 October 2024 © The Author(s) 2024, corrected publication 2024  \nAbstract  \nBackground and Objective Tucatinib is a highly selective, oral, reversible, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor. Tucatinib is approved at a 300-mg twice-daily dose in adults in combination with trastuzumab and capecitabine for advanced HER2-postitive (HER2+) unresectable or metastatic breast cancer and in combination with trastuzumab for RAS wild-type HER2+ unresectable or metastatic colorectal cancer. This study sought to characterize the pharmacokinetics (PK) and assess sources of PK variability of tucatinib in healthy volunteers and in patients with HER2+ metastatic breast or colorectal cancers.  \nMethods A population pharmacokinetic model was developed based on data from four healthy participant studies and three studies in patients with either HER2+ metastatic breast cancer or metastatic colorectal cancer using a nonlinear mixed-effects modeling approach. Clinically relevant covariates were evaluated to assess their impact on exposure, and overall model performance was evaluated by prediction-corrected visual predictive checks.  \nResults A two-compartment pharmacokinetic model with linear elimination and first-order absorption preceded by a lag time adequately described tucatinib pharmacokinetic profiles in 151 healthy participants and 132 patients. Tumor type was identified as a significant covariate affecting tucatinib bioavailability and clearance, resulting in a 1.2-fold and 2.1-fold increase in tucatinib steady-state exposure (area under the concentration–time curve) in HER2+ metastatic colorectal cancer and HER2+ metastatic breast cancer, respectively, compared with healthy participants. No other covariates, including mild renal or hepatic impairment, had an impact on tucatinib pharmacokinetics.  \nConclusions The impact of statistically significant covariates identified was not considered clinically meaningful. No tucatinib dose adjustments are required based on the covariates tested in the final population pharmacokinetic model.  \nClinical Trial Registration NCT03723395, NCT03914755, NCT03826602, NCT03043313, NCT01983501, NCT02025192 .  \n1 Introduction  \nTucatinib is a highly selective, oral, reversible, small-molecule human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor. Tucatinib is approved at a 300-mg twice-daily (BID) oral (PO) dose without regard to food in combination with trastuzumab and capecitabine in adult patients with advanced unresectable or metastatic HER2-postitive (HER2+) breast cancer (including those with brain metastases) who have received at least one prior anti-HER2-based regimenin the metastatic setting [1–3]. Its approval also includes the use of tucatinib 300 mg BID in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2+ unresectable or metastatic colorectal cancer (mCRC) that has progressed after treatment with fluoropyrimidine-based, oxaliplatin-based, and irinotecan-based chemotherapy [4, 5].  \nExtended author information available on the last page of the article  \nThe maximum tolerated dose of tucatinib was established as PO 300 mg BID in two previously conducted phase Ib studies in patients with HER2+ metastatic breast cancer (mBC), ONT-380-004 (NCT01983501, tucatinib + trastuzumab emtansine [T-DM1]) and ONT-380-005 (NCT02025192, tucatinib + trastuzumab + capecitabine)  \n[6] .  \nIn the HER2CLIMB phase II study (ONT-380-206, NCT02614794), tucatinib was evaluated in combination with trastuzuma","cbCairVLdgn6KhOL","https://ap.wps.com/l/cbCairVLdgn6KhOL","pdf",1311132,11,"English","# Abstract\n## Background and Objective\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Key Points","[{\"question\":\"What was the main goal of this population pharmacokinetic analysis of tucatinib?\",\"answer\":\"To characterize tucatinib pharmacokinetics and identify sources of pharmacokinetic variability in healthy participants and patients with HER2+ metastatic breast or colorectal cancer.\"},{\"question\":\"How was the population pharmacokinetic model constructed and evaluated?\",\"answer\":\"A population pharmacokinetic model was developed using nonlinear mixed-effects modeling from four healthy participant studies and three patient studies, then assessed with prediction-corrected visual predictive checks.\"},{\"question\":\"Which factors significantly influenced tucatinib exposure in the final model?\",\"answer\":\"Tumor type was identified as a significant covariate affecting bioavailability and clearance, increasing steady-state exposure in HER2+ metastatic colorectal and breast cancer compared with healthy participants.\"},{\"question\":\"Do clinicians need to adjust the tucatinib dose based on the covariates tested?\",\"answer\":\"No. The statistically significant covariate effects were not considered clinically meaningful, and no dose adjustments were required based on the covariates evaluated in the final model.\"}]","Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer | PDF",1790017128,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfe4b151ab87d40ac4cf6f6df03acdcb.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8af1a4c9866b88aa1c39cfc2f9bcb7a.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f36cb157bc023035720abeb1cfa990f.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3297f4779b4571a4ec6ef9a162f28c0b.webp",980,1301]